Carlyle Acquires Abingworth to Expand Global Healthcare & Life Sciences Investing
August 3, 2022
Global investment firm Carlyle has acquired Abingworth, a transatlantic life sciences investment firm with about $2 billion in assets under management, to broaden Carlyle's healthcare franchise and capabilities across venture to buyouts. The deal brings Abingworth's specialized team and clinical co-development expertise into Carlyle and establishes Launch Therapeutics, an operating company to accelerate late-stage clinical development; terms were not disclosed.
- Buyers
- Carlyle
- Targets
- Abingworth
- Industry
- Healthcare Services
- Location
- United Kingdom
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
The Carlyle Group Acquires Majority Stake in TriNetX
September 21, 2020
Healthcare Services
The Carlyle Group has made a strategic growth investment to acquire a majority stake in TriNetX, a global health research network that provides real-world clinical and claims data and analytics. Carlyle's investment will accelerate TriNetX's development of clinical research capabilities, support global expansion, and fund both organic and inorganic growth opportunities.
-
Carlyle Leads Majority Growth Investment in Saama Technologies
October 20, 2021
AI & Machine Learning
Global investment firm Carlyle led a strategic growth investment of up to $430 million to acquire a majority stake in Saama Technologies. A syndicate of healthcare-focused investors — including Amgen Ventures, Intermountain Ventures, Merck Global Health Innovation Fund, McKesson Ventures, Northpond Ventures, Pfizer Ventures and Population Health Partners — will co-invest to accelerate Saama's AI-driven Life Science Analytics Cloud and expand go-to-market and R&D capabilities.
-
Carlyle Acquires Majority Stake in Sciens Building Solutions
November 9, 2021
Industrial Services
Funds managed by global investment firm Carlyle acquired a majority stake in Sciens Building Solutions from Huron Capital, with Sciens' senior management and Huron retaining minority equity and a board seat. The investment will support Sciens' growth strategy — accelerating organic investment and M&A to expand its fire and life safety platform across commercial, institutional and government end markets. Terms were not disclosed.
-
Carlyle and SK Capital Acquire bluebird bio
May 14, 2025
Biotechnology
Funds managed by The Carlyle Group and SK Capital Partners have completed a takeover of bluebird bio, taking the Somerville, Massachusetts-based gene therapy company private. The deal provides significant primary capital and a new management team led by David Meek to scale commercial delivery, expand manufacturing capacity, and stabilize bluebird's financial position following liquidity concerns.
-
Carlyle Acquires Majority Stake in Incubeta
November 16, 2022
Marketing & Advertising
The Carlyle Group, via its Carlyle Europe Technology Partners platform, has agreed to acquire a majority stake in Incubeta, a London-headquartered digital marketing and ad-tech agency. Carlyle will support Incubeta's international growth, investments in proprietary technology and commercial operations, and M&A-led market consolidation; terms were not disclosed.
-
The Carlyle Group Acquires Unchained Labs
April 26, 2021
Medical Devices
The Carlyle Group agreed to acquire life sciences tools company Unchained Labs for $435 million from Novo Holdings A/S, Canaan Partners and TPG Biotech, in a transaction expected to close in Q2 2021. Carlyle will partner with Unchained Labs' management to accelerate organic and inorganic growth through investments in R&D, digitization and geographic expansion; Unchained is headquartered in Pleasanton, California and had ~170 employees and ~$75M revenue projected for 2021.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.